
Opinion|Videos|December 8, 2023
Evaluating the Impact of Elacestrant Use in Clinical Practice for Patients With ER+/HER2-Metastasized Breast Cancer
Author(s)Joyce O'Shaughnessy, MD
Identifying the impact of elacestrant in clinical practice for patients with ER+/HER2- metastatic breast cancer.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Rezatapopt Shows 46% ORR in TP53 Y220C–Mutated Ovarian Cancer
2
First-Line Savolitinib/Osimertinib Improves PFS in MET+ NSCLC
3
Hypoxia Tracer Gets FDA Breakthrough Status in HPV+ Oropharyngeal Cancer
4
G2032R Resistance Data Is Reshaping Second-Line Sequencing in ROS1+ NSCLC
5

































